Innovating Works

PhilPharm

Financiado
Philosophy of Pharmacology Safety Statistical standards and Evidence Amalgamat...
"The project intends addresses safety assessment in pharmacology with a view on philosophical work on causality and causal inference from statistical data ((Pearl 2000; Spirtes, Glymour, Scheines 2000, Woodward 2003, Cartwright, 2... "The project intends addresses safety assessment in pharmacology with a view on philosophical work on causality and causal inference from statistical data ((Pearl 2000; Spirtes, Glymour, Scheines 2000, Woodward 2003, Cartwright, 2007b). This interest is motivated by the fact that current evidence standards emphasize internal validity of studies and hence randomization, disregarding alternative routes to causal assessment, such as the joint support of different sorts of evidence to a given hypothesis. This may be particularly detrimental in that, much of the evidence for harms comes from anecdotal reports, case series, or survey data, which standard guidelines of evidence evaluation regard as being of poorer quality with respect to controlled (randomized) experiments. Although the role of this ""lower level"" evidence is increasingly acknowledged to be a valid source of information for the risk profile of medications (Howick et al. 2009, Hauben and Aronson, 2007), current practices have difficulty in assigning it a precise epistemic status and integrating it with more standard methods of hypothesis testing. The philosophical debate has already addressed similar questions in relation to the assessment of treatment efficacy (Worral 2010, Papineau, 1993; Cartwright, 2007). However, none of these contributions expressly addresses the specific issues arising in causal assessment for harms. The project intends to change the evidence standards for safety assessment by providing a unified framework for the amalgamation of diverse evidence in safety assessment. In particular, the project intends to: 1) present a foundational analysis on statistical/causal inference with a focus on safety assessment; 2) Build a unified epistemic framework within which different kinds of evidence can be combined and used for decision; 3) Provide the theoretical framework for the development of new standards of drug evaluation. " ver más
31/03/2020
UNIVPM
2M€
Duración del proyecto: 60 meses Fecha Inicio: 2015-03-17
Fecha Fin: 2020-03-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2020-03-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-StG-2014: ERC Starting Grant
Cerrada hace 10 años
Presupuesto El presupuesto total del proyecto asciende a 2M€
Líder del proyecto
UNIVERSITA POLITECNICA DELLE MARCHE No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5